Peptide record

TPDB26033

Antibacterial Antiviral Toxicity modified_plain modified
42 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB26033
Antibacterial Antiviral Toxicity
Anti-infective peptides Toxicity and safety peptides
Peptipedia DRAVP 2.0
modified_plain
Yes
A 42-aa modified multi-activity (Antibacterial, Antiviral, and Toxicity) peptide sequence curated from Peptipedia and DRAVP 2.0, with an available 3D structural model.
Modified, details unspecified
Sequence
VALDPIDISIVLNKAKSDLEESKEWIRRSNGKLDSIGSGSGX
Physicochemical Analysis
C190H318N54O65
CQHMFTY
S
4398.94
4.84
6
7
14
-1
12.96
-0.383
102.14
Mammalian: 100 hour Yeast: >20 hour E.coli: >10 hour
5500
125.03
9
Residue Composition
number
2
A
2
R
2
N
4
D
0
C
3
E
0
Q
4
G
0
H
5
I
4
L
4
K
0
M
0
F
1
P
7
S
0
T
1
W
0
Y
2
V
Amino Acid Distribution
A: 2 R: 2 N: 2 D: 4 C: 0 E: 3 Q: 0 G: 4 H: 0 I: 5 L: 4 K: 4 M: 0 F: 0 P: 1 S: 7 T: 0 W: 1 Y: 0 V: 2
Chemical Descriptors
42
C190H318N54O65
4398.94
4.84
-1
12.96
-0.383
Evidence Records 3 records
Evidence 1 Activity

Activity

50% Cytotoxicity
Toxicity
10 µM
Cytotoxic
50% Cytotoxicity | 10 | µM | target cell: Vero cells

Target

Vero cells

Source & Reference

NA
DBAASP
Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides. | Sci Rep | 2017
Evidence 2 Activity

Activity

50% Cytotoxicity
Toxicity
4.5 µM
Cytotoxic
50% Cytotoxicity | 4.5 | µM | target cell: Vero cells

Target

Vero cells

Source & Reference

NA
DBAASP
Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides. | Sci Rep | 2017
Evidence 3 Activity

Activity

50% Cytotoxicity
Toxicity
1.3 µM
Cytotoxic
50% Cytotoxicity | 1.3 | µM | target cell: Vero cells

Target

Vero cells

Source & Reference

NA
DBAASP
Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides. | Sci Rep | 2017